Selected article for: "blood test and comprehensive blood test"

Title: RESEARCH COMMUNICATIONS OF THE 28th ECVIM-CA CONGRESS
  • Document date: 2018_12_19
  • ID: r79h9yzz_217
    Snippet: In referred dogs with MMVD, eight client‐owned dogs have been treated with a regimen of overdose of pimobendan (case patients; 0.9~2.7mg/kg daily for 60~240 days). Among patients treated with a recommended dosage of pimobendan (0.4~0.6mg/kg daily for 60~345 days), controls (n=12) were selected based on matching variables such as signalment/medical history, physical examination findings, and severity of CHF. For the initial analysis of homogenei.....
    Document: In referred dogs with MMVD, eight client‐owned dogs have been treated with a regimen of overdose of pimobendan (case patients; 0.9~2.7mg/kg daily for 60~240 days). Among patients treated with a recommended dosage of pimobendan (0.4~0.6mg/kg daily for 60~345 days), controls (n=12) were selected based on matching variables such as signalment/medical history, physical examination findings, and severity of CHF. For the initial analysis of homogeneity between case and control groups, comprehensive blood test profile (CBC, serum biochemistry, NT‐proBNP, SDMA), electrocardiographic, radiographic, and echocardiographic data were collected. Serum cardiac troponin I (cTnI) and QTc interval values (formula of Van de Water) were compared between groups. In addition, these two endpoints were analyzed to assess the relationship to the dosage and the duration of administration of pimobendan in the case patients.

    Search related documents:
    Co phrase search for related documents